Vimta Labs Quarterly Results for Trading Insights
In Sept 2024, Vimta Labs (VIMTALABS) reported revenue ₹85 Cr and net profit ₹15 Cr — revenue +25.0% YoY. For annual financials, live price and key ratios, visit VIMTALABS screener.
VIMTALABS Quarterly Results — Revenue, Profit & EPS Highlights
Vimta Labs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore VIMTALABS price movement history to track price trends across different timeframes.
- Revenue of ₹85 Cr in Sept 2024 (+6.2% vs Mar 2024, +25.0% vs Sept 2023)
- Net Profit of ₹15 Cr in Sept 2024 (+25.0% vs Mar 2024, +150.0% vs Sept 2023)
- EBITDA of ₹29 Cr in Sept 2024 (+16.0% vs Mar 2024)
- Operating Margin of 33.0% in Sept 2024 (+2.0pp vs Mar 2024)
- Earnings Per Share of ₹6.88 in Sept 2024 (+23.3% vs Mar 2024)
Vimta Labs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VIMTALABS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 85 | 80 | 76 | 95 | 68 | 6.3% | 25.0% |
| Net Profit (₹ Cr) | 15 | 12 | 12 | 22 | 6 | - | - |
| EBITDA (₹ Cr) | 29 | 25 | 25 | 38 | 18 | - | - |
| EPS (₹) | 6.88 | 5.58 | 5.54 | 9.65 | 2.86 | - | - |
| Operating Margin (%) | 33.0% | 31.0% | 32.0% | 37.0% | 24.0% | - | - |
VIMTALABS Share Price Trend — 1-Year Movement Across Quarterly Results
Vimta Labs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with Vimta Labs value estimation to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VIMTALABS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vimta Labs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1799.2 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 159.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6667.0 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 235.5 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4410.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 383.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1401.0 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 203.9 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1303.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 491.9 |
All amounts in ₹ Crores